A-674563

• Description:

  A-674563 is an orally active Akt1 inhibitor with a Ki of 11 nM.

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Akt

• Type:

  Reference compound

• Related Pathways:

  PI3K/Akt/mTOR

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/a-674563.html

• Purity:

  99.87

• Solubility:

  DMSO : 83.33 mg/mL (ultrasonic)

• Smiles:

  N[C@@H](CC1=CC=CC=C1)COC2=CC(C3=CC4=C(C=C3)NN=C4C)=CN=C2

• Molecular Formula:

  C22H22N4O

• Molecular Weight:

  358.44

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Luo Y, et al. Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol Cancer Ther, 2005, 4 (6), 977-986.|[2]Zhu QS, et al. Soft tissue sarcoma cells are highly sensitive to AKT blockade: a role for p53-independent up-regulation of GADD45 alpha. Cancer Res, 2008, 68 (8), 2895-2903.|[3]Zou Y, et al. Pre-clinical assessment of A-674563 as an anti-melanoma agent. Biochem Biophys Res Commun. 2016 Aug 12;477 (1) :1-8.|[4]Xu L, et al. Concurrent targeting Akt and sphingosine kinase 1 by A-674563 in acute myeloid leukemia cells. Biochem Biophys Res Commun. 2016 Apr 15;472 (4) :662-8.|[5]Wang A, et al. Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML. Oncotarget. 2016 May 17;7 (20) :29131-42.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  Akt1

• Citation 01:

  Cell Commun Signal. 2025 Apr 23;23 (1) :194.|Cell Signal. 2023 Sep:109:110753.|J Proteome Res. 2018 Oct 5;17 (10) :3360-3369.|Oncotarget. 2016 May 17;7 (20) :29131-42. |Aging. 2020 Nov 17;12 (22) :23114-23128.

• CAS Number:

  [552325-73-2]